KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Cash from Financing Activities: 2019-2024

Historic Cash from Financing Activities for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Dec 2024 value amounting to $304.1 million.

  • Recursion Pharmaceuticals' Cash from Financing Activities rose 1426.79% to $251.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $400.2 million, marking a year-over-year increase of 6.96%. This contributed to the annual value of $304.1 million for FY2024, which is 117.02% up from last year.
  • Recursion Pharmaceuticals' Cash from Financing Activities amounted to $304.1 million in FY2024, which was up 117.02% from $140.1 million recorded in FY2023.
  • Recursion Pharmaceuticals' Cash from Financing Activities' 5-year high stood at $458.5 million during FY2021, with a 5-year trough of $140.1 million in FY2023.
  • Its 3-year average for Cash from Financing Activities is $199.5 million, with a median of $154.3 million in 2022.
  • Per our database at Business Quant, Recursion Pharmaceuticals' Cash from Financing Activities tumbled by 66.34% in 2022 and then spiked by 117.02% in 2024.
  • Recursion Pharmaceuticals' Cash from Financing Activities (Yearly) stood at $246.1 million in 2020, then soared by 86.30% to $458.5 million in 2021, then slumped by 66.34% to $154.3 million in 2022, then fell by 9.21% to $140.1 million in 2023, then soared by 117.02% to $304.1 million in 2024.